Comparative Pharmacology
Head-to-head clinical analysis: ERYPAR versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPAR versus ERYTHROCIN STEARATE.
ERYPAR vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic